Search
I-Mab
IMABAdd to Watchlist
4.630USD
0.0000.00%
Close 06/18, 16:00（ET）Quotes delayed by 15 min
173.47MMarket Cap
LossP/E TTM
Earnings Forecast
Currency: USD Updated:Analyst Rating
Based on
5
analysts
Buy
Current Rating
8.400
Target Price
+435.03%
Upside Space
Strong Buy
Buy
Hold
Sell
Strong Sell
Peer Comparison
175
Total
6
Median
8
Average
Company name
Ratings
Analysts
I-Mab
IMAB
5
Biogen Inc
BIIB
38
Amgen Inc
AMGN
38
Eli Lilly and Co
LLY
35
AbbVie Inc
ABBV
34
Vertex Pharmaceuticals Inc
VRTX
34
1
2
3
...
35
Support & Resistance
Relevant data have not been disclosed by the company yet.
Financial Forecasting
EPS
Revenue
Net Profit
EBIT
Forecast
Actual
Data disclaimer: Analyst ratings and target prices are provided by LSEG for informational purposes only and do not constitute investment advice.
FAQs
What is I-Mab's price target?
Analysts forecast that I-Mab's price target is USD 8.50, with the highest forecast at USD 10.00 and the lowest forecast at USD 7.00.
How have I-MabIMAB's recent earnings per share performed?
The market expectation was USD -0.27, while I-MabIMAB's earnings per share (EPS) for the previous quarter was USD -0.07. EPS for the next quarter is expected at USD -0.13.
What is the analyst rating for I-Mab?
Based on the ratings of I-Mab's stock from 5 analysts, most analysts support a Buy trend. After considering the opinions of other analysts, we ultimately rate Apple's stock as Buy. Please note that this is not trading advice. You still need to conduct your own analysis.
